Navigation Links
Bionovo's Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
Date:7/17/2009

EMERYVILLE, Calif., July 17 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today that a study of the gene regulation in multiple cell lines by several of their estrogen receptor beta (ERb) candidates will be published in Public Library of Science One.

"In this study we show that plant-derived ERb compounds are as selective as synthetic compounds, but regulate different genes. Specifically, we have discovered that these compounds do not promote breast or endometrial cancer in animal models, unlike many estrogen therapies. This suggests that these plant-derived ERb-selective compounds could lead to safer, more attractive alternative therapies for menopausal symptoms," said Dr. Dale Leitman, the Principal Investigator of the study.

The publication describes the analyses of three distinct classes of ERb selective drugs. The study determines the relative ER selectivity and pattern of gene expression of the three classes of ERb selective compounds compared to the natural hormone estradiol, which non-selectively regulates both ERa and ERb . The most significant finding in the study was that the ERb-selective compounds regulate a number of genes differently than estradiol, a hormone therapy commonly used to treat women's health issues. This discovery indicates that ERb agonists might be safer than current estrogens used in hormone therapy. The study also demonstrates the cell type selectivity of Menerba (MF101) and Liquiritigenin, two of Bionovo's ERb selective drugs, in different cell types. These compelling findings will serve as a strong impetus for Bionovo, Inc. to continue investigating the unique abilities of their drugs to safely and effectively treat menopausal symptoms.

"It is essential that new drug candidates demonstrate drug selectivity and tissue specificity in order to minimize adverse effects, particularly when the drug is being developed for the treatment of common, recurring symptoms associated with menopause, such as hot flashes. This is particularly important when developing drugs that mediate their effects through estrogen receptors, which are responsible for many functions in the body and are present in a range of different tissues. Bionovo stands alone in its dedication to identifying novel pathways in estrogen receptor signaling as drug targets for the treatment of women's conditions," said Isaac Cohen, Chairman and CEO of Bionovo, Inc. "We have been endeavoring to develop more selective drugs in women's health, and Dr. Leitman's study highlights the solid scientific underpinnings of our ER beta selective drugs and underlines the deep biological understanding we have of the mechanisms through which they work."

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI".

For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery
2. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
3. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
4. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
5. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
6. One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials
7. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
8. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
9. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
10. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
11. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
(Date:5/26/2016)... 26, 2016   Change Healthcare , ... network solutions and technology-enabled services designed to ... into a strategic channel partnership with SourceMed, ... solutions and revenue cycle management services that ... rehabilitation clinics to optimize revenue, operational efficiency ...
(Date:5/25/2016)... , May 25,2016 FDA ... near-infrared Cellvizio platform for urological and surgical applications ... MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... milestone in the US with the 12 th ... Drug Administration (FDA). This new FDA clearance covers ...
Breaking Medicine Technology:
(Date:5/29/2016)... ... May 29, 2016 , ... "With 30 unique self-animating web themed intros and ... of their project," said Christina Austin - CEO of Pixel Film Studios. , ... for use in Final Cut Pro X. Pixel Film Studios’ minimalistic titles allow users ...
(Date:5/28/2016)... ... ... city where’s it’s easy to spot the neon lights of chains serving fast food, one ... a taste for real food. , On May 13, the Best Western Plus ... restaurant focusing on dishes made by hand with wholesome, organic ingredients that are sourced locally ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses ... time to shed lights on the variety of topics detailing why we appreciate nurses ... tackles why this career has gone from being in a major recession to one ...
(Date:5/27/2016)... ... ... Beleza Medspa has initiated a new program to assist active duty ... that Coolsculpting is being used for for more than just cosmetic purposes. ... prescribed body-fat standard, measured by the circumference-based tape method. The tape-test is used ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
Breaking Medicine News(10 mins):